What's Coming Next

Reading the next few years without the hype

If you spend any time in mom groups, you have seen the breathless posts: a pill that beats the shot, a drug that melts twice as much, the “Ozempic killer.” Most of it is investor chatter dressed up as health news. But underneath the noise is a genuinely busy pipeline, and a mother deciding whether to start now or wait deserves the real trial numbers, not the headlines. Here is what is actually coming, in plain language, with the data attached. One caveat to hold throughout: these trials were run in adults with obesity or diabetes, generally not in pregnant or breastfeeding women, so “what's coming” is about options, not a green light for every situation.

What a pill is actually worth, according to people asked

Before the trial numbers, it is worth establishing something the coverage takes for granted: how much people actually care about swallowing versus injecting. Somebody measured it.

In a discrete choice experiment, 500 respondents with type 2 diabetes were shown unlabeled treatment profiles built from real head-to-head trial data and asked to choose⁶. The single most important attribute in their decisions was not weight change and not blood-sugar control — it was mode and frequency of administration, which accounted for 49.1% of the decision weight, ahead of nausea risk at 30.8%, weight change at 11.3% and HbA1c change at 8.8%. Given a choice between an oral profile and an injectable one, 91.0% preferred the tablet. The gap in willingness to start at all was starker still: 62.4% said they would initiate the oral profile against 13.6% for the injectable one.

Two honest caveats before anyone builds a plan on that. These were Japanese patients with type 2 diabetes, 93.8% of them men, none of whom had ever used an injectable — a group about as far from this magazine's reader as a sample gets. And stated preference is not behavior; what people say in a survey and what they stick with are different measurements.

But the direction is not in doubt, and it reframes the whole pipeline. Half the decision is about the delivery. A drug that loses a couple of percentage points of efficacy and removes the needle is not a worse drug for a woman who was never going to start the injectable one.

The one everyone was waiting for: both pills landed

The single biggest shift was oral, and it has already happened. Both pills are approved and prescribable in the US: Wegovy tablets (oral semaglutide) since 22 December 2025, and Foundayo (orforglipron) since 1 April 2026⁸.

One correction worth carrying, because the figures in circulation for both are doses that were never approved. Oral semaglutide was studied at 50 mg and produced about 15% weight loss in its OASIS 1 trial¹. The dose that reached pharmacies is 25 mg, and in the trial behind the approval it produced a 13.6% mean weight change against 2.4% on placebo over 64 weeks in 307 patients — with nearly six in ten losing at least a tenth of their body weight, against about one in seven on placebo⁹. Still right alongside the injection. Just not the number you have been reading.

The more disruptive pill is orforglipron, a small molecule that, unlike oral semaglutide, has no food-and-water timing rules and is far easier to manufacture at scale. Trial coverage quotes a 36 mg dose and about 11% at 72 weeks². The approved label tops out at 17.2 mg, where its own trial of 3,127 adults recorded 11.1% against 2.1% on placebo¹⁰. Same ballpark, different number on the bottle — and a genuinely convenient daily pill with no injection and no fasting window is a different kind of product for a mother's actual life, which is exactly why the no-injection question matters as much as the raw percentage.

For a lot of mothers the real breakthrough is not a bigger number — it is a pill you can take without a needle, a fasting window, or a second thought.

Approval is not the same as access, and the compounded lane has not gone anywhere: Open Water Rx sells a $279/mo oral compounded semaglutide tablet, against its own $249/mo injection — a real trade-off if the needle, not the timeline, is what is holding you back. NuuVim goes further, pricing its oral and injectable forms identically on both molecules — $79/mo semaglutide, $133/mo tirzepatide either way — though that is a new-patient tier with no published refill rate. Neither is the approved tablet, and now that a real one exists, that is worth naming out loud when you ask.

The heavy hitters: stacking more hormones

The other frontier is not about delivery but about power, achieved by combining hormones. Today's strongest approved drug, tirzepatide, already pairs two gut hormones and reached roughly 21% weight loss in its pivotal trial³. The next generation stacks more.

Retatrutide adds a third hormone (a “triple agonist”). In its phase 2 trial, the highest dose produced a striking average weight reduction of about 24% at 48 weeks⁴ — the largest figures the field has seen from a medication, though phase 2 results still need confirmation in the larger phase 3 program underway. CagriSema takes a different route, combining semaglutide with a second hormone called an amylin analogue; in a phase 3 trial in adults with type 2 diabetes it reduced body weight by about 14% while sharply improving blood sugar⁵. Diabetes trials tend to show smaller weight numbers than obesity trials, so read that figure in context.

What the headline numbers leave out

Every figure above is an average, and averages hide the people who left. The trials record that too, and it is the part the investor chatter never quotes.

In the orforglipron phase 3 obesity trial, adverse events led to treatment discontinuation in 5.3% to 10.3% of participants depending on dose, against 2.7% on placebo — and the most common problems participants reported were gastrointestinal, mostly mild to moderate². That is the real texture of a "convenient daily pill": for most people it is tolerable, and for roughly one in ten at the top dose it was not.

Staying on the drug is the other half. In a real-world analysis of 10,649 US active-duty service members who started a GLP-1 for weight management between 2021 and 2025, one-year persistence ranged from 81.9% on tirzepatide and 70.7% on semaglutide down to 34.2% on liraglutide, the older daily injection⁷. It is a narrow population — young, insured, medically supervised, and not a stand-in for a working mother's life — but the spread is the point. Two-thirds of the people on the daily drug were gone within a year. Convenience is not a nice-to-have; it is most of the outcome.

What this means for a mother deciding today

So should you wait? Usually not for its own sake. The best drug is the one you can actually get, afford, and stay on — and the approved options today are already highly effective. The pipeline mostly changes the odds that, a year or two out, there will be a more convenient pill or a more powerful combination, likely at a similar or better price as competition grows.

The more useful question is not what is coming but what would you still be taking in eighteen months. If the honest answer is "not a weekly injection," that is real information about you, and it is worth saying out loud to a prescriber now rather than discovering it in month four. A conversation about what you will realistically sustain is a better use of an appointment than a conversation about a molecule no regulator has cleared yet. Whatever you land on today, price it the way you'd price the pipeline itself — as a number that has to hold for eighteen months, not just the first one. TeleHealth Med states a flat "same price all" rate with no membership fees, which is the kind of legible pricing worth comparing any newer option against.